Agenus
Overview
Agenus is an immuno-oncology company designed to deliver innovation with speed for patients with cancer. We have a unique portfolio of antibodies, vaccines, cell therapies and adjuvants designed to treat cancers with optimal combinations.
Features
In addition to our broad portfolio, we have an accomplished team of scientists, novel technology platforms and end-to-end capabilities from new target discovery to GMP manufacturing. We believe that combination therapies and a deep understanding of each patient’s cancer will be key drivers of success in substantially expanding the patient population benefiting from current immuno-oncology therapies. At Agenus, we believe we have assembled the capabilities to bring curative treatments to patients.STO Details
Pre-sale
- Pre-sale start date TBA
- Pre-sale end date TBA
- Pre-sale token supply —
Token Sale
- STO start date Feb 19, 2019
- STO end date Apr 30, 2019
- STO token supply 100,000,000
- Soft cap TBA
- Hard cap size $100,000,000
Token details
- Ticker BEST
- Type ERC20
- Additional Token Emission No
- Accepted Currencies USD
- Token distribution Smart Contract
Legal
- Country Limitations —
- Registration Country United States
- Registration Year 2013
Rating Review and Analytics
- Investment Rating —
- Traction Low
- Risk Score —
Agenus Contacts
Ended 2090 days before $100,000,000
- Start STO Feb 19, 2019
- End STO Apr 30, 2019
- Funding type —
- Token BEST
- Price —
- Minimum investment —
- Product Type Digital Asset
- KYC Yes
- Whitepaper View
STOs that might interest you
- Status Ended 2211 days before
- Traction Low
- Risk Score —
- Registration Year 2018
- Status TBA
- Traction Low
- Risk Score —
- Registration Year 2015
- Status TBA
- Traction Low
- Risk Score —
- Registration Year 2016